Literature DB >> 2316795

Pharmacokinetics of three commercial antivenoms in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma, in Thailand.

M Ho1, K Silamut, N J White, J Karbwang, S Looareesuwan, R E Phillips, D A Warrell.   

Abstract

The pharmacokinetics of 3 monospecific antivenoms were compared in patients envenomed by the Malayan pit viper, Calloselasma rhodostoma. There was a biphasic decline in serum concentrations following intravenous administration. The initial rapid decline was attributable to the formation of venom-antivenom complexes, as the fall in antivenom during this phase was positively correlated with the initial venom concentration (P = 0.045). The total apparent volume of distribution for each antivenom was 1.5-3 times larger than that of the central compartment, which suggests some tissue distribution in addition to complex formation. This was marked for antivenom from the Government Pharmaceutical Organization of Thailand which contained mostly F(ab)2 fragments. The terminal elimination half time was shorter for Twyford antivenom of caprine origin. Systemic clearance was lower for Thai Red Cross antivenom. In 8 of the 26 patients who experienced recurrence of non-clotting blood after initial response to antivenom, serial measurements of plasma venom and antivenom concentrations revealed that recurrence of venom antigenemia and non-clotting blood bore no direct relation to the elimination half-life of the antivenom used, but non-clotting blood recurred when serum antivenom levels fell below 10-20% of the total given. There is no substitute for close monitoring of envenomed patients so that indications for further antivenom can be detected promptly.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2316795     DOI: 10.4269/ajtmh.1990.42.260

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.

Authors:  José María Gutiérrez; Guillermo León; Bruno Lomonte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

Authors:  Yeamin Huh; David E Smith; Meihau Rose Feng
Journal:  Xenobiotica       Date:  2011-09-05       Impact factor: 1.908

3.  Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria.

Authors:  Isa S Abubakar; Saidu B Abubakar; Abdulrazaq G Habib; Abdulsalam Nasidi; Nandul Durfa; Peter O Yusuf; Solomon Larnyang; John Garnvwa; Elijah Sokomba; Lateef Salako; R David G Theakston; Ed Juszczak; Nicola Alder; David A Warrell
Journal:  PLoS Negl Trop Dis       Date:  2010-07-27

4.  Antivenoms for Snakebite Envenoming: What Is in the Research Pipeline?

Authors:  Emilie Alirol; Pauline Lechevalier; Federica Zamatto; François Chappuis; Gabriel Alcoba; Julien Potet
Journal:  PLoS Negl Trop Dis       Date:  2015-09-10

5.  Population Pharmacokinetics of an Indian F(ab')2 Snake Antivenom in Patients with Russell's Viper (Daboia russelii) Bites.

Authors:  Geoffrey K Isbister; Kalana Maduwage; Ana Saiao; Nicholas A Buckley; Shaluka F Jayamanne; Shahmy Seyed; Fahim Mohamed; Umesh Chathuranga; Alexandre Mendes; Chandana Abeysinghe; Harindra Karunathilake; Indika Gawarammana; David G Lalloo; H Janaka de Silva
Journal:  PLoS Negl Trop Dis       Date:  2015-07-02

Review 6.  Diagnosis of snakebite and the importance of immunological tests in venom research.

Authors:  R David G Theakston; Gavin D Laing
Journal:  Toxins (Basel)       Date:  2014-05-23       Impact factor: 4.546

7.  Detection of venom after antivenom is not associated with persistent coagulopathy in a prospective cohort of Russell's viper (Daboia russelii) envenomings.

Authors:  Kalana Maduwage; Margaret A O'Leary; Fiona E Scorgie; Seyed Shahmy; Fahim Mohamed; Chandana Abeysinghe; Harindra Karunathilake; Lisa F Lincz; Christeine A Gnanathasan; Geoffrey K Isbister
Journal:  PLoS Negl Trop Dis       Date:  2014-12-18

Review 8.  Toxin Neutralization Using Alternative Binding Proteins.

Authors:  Timothy Patrick Jenkins; Thomas Fryer; Rasmus Ibsen Dehli; Jonas Arnold Jürgensen; Albert Fuglsang-Madsen; Sofie Føns; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2019-01-17       Impact factor: 4.546

9.  Effectiveness of repeated antivenom therapy for snakebite-related systemic complications.

Authors:  Kyung Hoon Park; Hyungoo Shin; Hyunggoo Kang; Changsun Kim; Hyuk Joong Choi; Kyunghun Yoo; Jaehoon Oh; Tae Ho Lim
Journal:  J Int Med Res       Date:  2019-08-26       Impact factor: 1.671

10.  A Single Dose of Viperfav(TM) May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation.

Authors:  Tihana Kurtović; Miran Brvar; Damjan Grenc; Maja Lang Balija; Igor Križaj; Beata Halassy
Journal:  Toxins (Basel)       Date:  2016-08-19       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.